the product in the database has an inactive status
indications:
Parkinson's disease: the drug is used in combination with levodopa and DOPA decarboxylase inhibitors or without inhibitors; monotherapy is used only in the early stages of the disease.
Composition:
1 tabl contains 5 mg of selegiline. The preparation contains lactose.
Action:
A selective, irreversible MAO inhibitor of type B. It increases the concentration of brain monoamines, mainly Dopamine, whose deficit in the basal ganglia is the most common cause of parkinsonian syndrome. The compensation of the Dopamine deficit is associated not only with MAO-B inhibition, but also with the inhibition of its secondary absorption by presynaptic receptors and facilitating its release and passage to postsynaptic receptors in the striatum. Selegiline increases the concentration of phenylethylamine in the brain, enhancing the postsynaptic activity of dopamine and norepinephrine. It also exerts neuroprotective effects by reducing the formation of free radicals in the tissues of the brain. It is well and quickly absorbed from the gastrointestinal tract. It is 94% bound to plasma proteins. It is metabolised in the liver to active metabolites (L-amphetamine, L-methamphetamine, N-desmethylselegiline). Metabolites reach their maximum concentration in the blood within 0.5-2 hours. T0,5 N-desmethyloselegiliny is 2 h, L-amphetamine - 17.7 h, L-methamphetamine - 20.5 h. The drug is excreted mainly in the urine.
Contraindications:
Hypersensitivity to selegiline or other components of the preparation. Disorders of extrapyramidal system and occurring with hyperkinetic hypotonic syndromes (eg chorea). Conditions of psychomotor agitation, manic and delusional states. Peptic ulcer of the stomach or duodenum. Do not use simultaneously with peptidine and other opioid medicines, selective serotonin reuptake inhibitors, MAO inhibitors, sumatriptan.
Precautions:
When combined with levodopa, dyskinesias, excitement, anxiety, insomnia and nausea may occur, and the dose of levodopa should be reduced. Caution use in patients with arrhythmias, angina pectoris, unstable hypertension, psychosis, impaired liver or kidney function. The efficacy and safety of the drug in children have not been established. Due to the lactose content, the preparation should not be used in patients with galactose intolerance, Lapp lactase deficiency or malabsorption of glucose-galactose.
Pregnancy and lactation:
Do not use during pregnancy and during breastfeeding.
Side effects:
They occur almost exclusively in combination with levodopa. The most common were dyskinesias; moreover, often: nausea, dizziness, confusion, hypotension, insomnia, hallucinations, dryness of the oral mucosa. There were also: tremor, choreosis, balance disorders, anxiety, blepharospasm, slowness, facial grimaces, myoclonic involuntary movements, stiff neck, dystonia, acceleration of gait, increased apraxia, muscle spasms, anxiety, depression, drowsiness, mood or behavior changes, nightmares, lethargy, fatigue, apathy, hyperactivity, sleep disturbances, transient irritability, headache, back pain, leg pain, migraine, tinnitus, burning of the throat, taste disorders, numbness of the back, chills, visual disturbances, sexual dysfunction, hypotension orthostatic, hypertension, arrhythmia, palpitations, angina pectoris, tachycardia, peripheral edema, sinus bradycardia, fainting, nausea, vomiting, constipation, weight loss, anorexia, decreased appetite, dysphagia, diarrhea, heartburn, rectal bleeding, exacerbation of peptic ulcer disease , gastrointestinal bleeding, slow mo delivery tenderness, hypertrophy of the prostate gland, urinary retention, nocturia, excessive sweating, hair loss, rash, hypersensitivity to light, asthma, shortness of breath, diplopia, speech disorders. Selegiline may increase the activity of liver enzymes in the blood.
Dosage:
Orally. Adults: usually 10 mg daily in 2 doses administered in the morning and early afternoon. Do not exceed the 10 mg / day dose, due to the risk of non-selective MAO inhibition.Selegiline, administered as a levodopa adjuvant, allows the dose of levodopa to be reduced by 10 to 30% during the course of continuous treatment.
(C)
